Earl J. Crain

Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies

Pancras C. Wong, Earl J. Crain, Bailong Xin et al. · Journal of Thrombosis and Haemostasis · 2008 · 299 citations · Full text

Thrombopoiesis, Thrombosis, Medicinal Chemistry +8

Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy

Andrew K. Dilger, Kumar B. Pabbisetty, James R. Corte et al. · Journal of Medicinal Chemistry · 2021 · 93 citations · Full text

A small-molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits

Pancras C. Wong, Earl J. Crain, Carol A. Watson et al. · Journal of Thrombosis and Thrombolysis · 2011 · 73 citations

Thrombosis, Blood Platelet, Medicine +9

Nonpeptide Factor Xa Inhibitors: I. Studies with SF303 and SK549, a New Class of Potent Antithrombotics

Pancras C. Wong, Mimi L. Quan, Earl J. Crain et al. · Journal of Pharmacology and Experimental Therapeutics · 2000 · 71 citations

Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits

Pancras C. Wong, Earl J. Crain, Carol A. Watson et al. · Journal of Thrombosis and Haemostasis · 2009 · 68 citations

Thrombosis, Thrombin Inhibitor Dabigatran, Hematology +9